

# Oncology Clinical Trials

## Breast

**VIKTORIA-1 (CELCUITY):** A Phase 3, two-part study comparing gedatolisib in combination with palbociclib and fulvestrant to standard-of-care therapies in patients with hr-positive, her2-negative advanced breast cancer previously treated with a cdk4/6 inhibitor in combination with non-steroidal aromatase inhibitor therapy.

[Learn more about VIKTORIA-1 \(CELCUITY\)](#)

**MA.39 (CCTG):** A randomized trial of regional radiotherapy in biomarker low risk node positive breast cancer.

[Learn more about MA.39 \(CCTG\)](#)

## Gastrointestinal

**CRC.10 (CCTG):** Colon adjuvant chemotherapy based on evaluation of residual disease (circulate – north america)

[Learn more about CRC.10 \(CCTG\)](#)

## Hematology

**MY.13 (CCTG):** A Phase 3 non-inferiority, randomized, controlled trial of fixed duration versus continuous daratumumab among transplant ineligible older adults with newly-diagnosed multiple myeloma

[Learn more about MY.13 \(CCTG\)](#)

**TAILOR (JANSSEN):** a Phase 2 study of customized ibrutinib treatment regimens for chronic lymphocytic leukemia

[Learn more about TAILOR \(JANSSEN\)](#)

## Radiotherapy

**COMET-3:** A Phase 3 randomized, controlled trial and economic evaluation of stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic (1-3 Metastases) cancer

[Learn more about COMET-3](#)

## For more information, contact:

**Khadija Al-Harazi**, Research Co-ordinator

[khadija.alharazi@niagarahealth.on.ca](mailto:khadija.alharazi@niagarahealth.on.ca)

905-378-4647 x45703

**Caitlin Leblanc**, Clinical Trials Nurse

[Caitlin.leblanc@niagarahealth.on.ca](mailto:Caitlin.leblanc@niagarahealth.on.ca)

905-378-4647 x43806